Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Cyclosporin, leflunomide and nitrogen mustard

Identifieur interne : 002B73 ( Main/Exploration ); précédent : 002B72; suivant : 002B74

Cyclosporin, leflunomide and nitrogen mustard

Auteurs : Daniel E. Furst

Source :

RBID : ISTEX:907ACA7F313227DDD461E60579F9FC6554E02941

English descriptors

Abstract

SummaryCyclosporin A (CSA)Cyclosporin inhibits IL-2 release and T-cell activation and, secondarily, affects B-cell function. It also inhibits bone resorption, at least in vitro.This drug's bio-availability averages 25–35% but is highly variable. Food and grapefruit juice enhance bio-availability and newer formulations may make its absorption more reliable. It is highly concentrated in fatty tissues and red blood cells but does not cross the blood-brain barrier. CSA is metabolized to numerous metabolites by the liver and its elimination half-life is 6–12 hours in the absence of severe liver disease. Biliary excretion accounts for 94% of CSAs elimination. Because it is highly metabolized, its metabolism can be inhibited by other drugs (e.g. ketoconazole and erythromycin) or its metabolism can be induced (e.g. anticonvulsants).Cyclosporin is more effective than placebo for the treatment of rheumatoid arthritis and as effective as other antirhematics. There is potential for the use of CSAs in DMARD combinations.The principal toxicities of cyclosporin are gastro-intestinal and renal, with the latter being of more concern.Leflunomide (LF)Leflunomide may be a pyrinidine synthesis inhibitor, although tyrosine kinase inhibition may also be part of its mechanism of action.its active metabolite is excreted renally to a large degree, with a prolonged elimination half-life of about 11 days. Since LF is activated by liver metabolism, renal failure may have less effect on kinetics than severe liver disease.Early data on efficacy indicate efficacy at 10–25 mg/day, although more well-controlled data is necessary.Toxicity relates to the skin, liver and GI tract, although some degree of weight loss was also found.Nitrogen mustard (NM)Nitrogen mustard is an alkylating agent whose pharmacokinetics are poorly understood. Small, open studies in RA indicate that NM has a potential for relatively rapid response (1–2 weeks) but, clearly, much work remains to be done.As an alkylating agent, GI and hematological toxicities are of greatest concern.

Url:
DOI: 10.1016/S0950-3579(05)80310-3


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Cyclosporin, leflunomide and nitrogen mustard</title>
<author>
<name sortKey="Furst, Daniel E" sort="Furst, Daniel E" uniqKey="Furst D" first="Daniel E." last="Furst">Daniel E. Furst</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:907ACA7F313227DDD461E60579F9FC6554E02941</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1016/S0950-3579(05)80310-3</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-W998MPMX-3/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002B07</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002B07</idno>
<idno type="wicri:Area/Istex/Curation">002B07</idno>
<idno type="wicri:Area/Istex/Checkpoint">001964</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001964</idno>
<idno type="wicri:doubleKey">0950-3579:1995:Furst D:cyclosporin:leflunomide:and</idno>
<idno type="wicri:Area/Main/Merge">002C31</idno>
<idno type="wicri:Area/Main/Curation">002B73</idno>
<idno type="wicri:Area/Main/Exploration">002B73</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Cyclosporin, leflunomide and nitrogen mustard</title>
<author>
<name sortKey="Furst, Daniel E" sort="Furst, Daniel E" uniqKey="Furst D" first="Daniel E." last="Furst">Daniel E. Furst</name>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Bailliere's Clinical Rheumatology</title>
<title level="j" type="abbrev">BACR</title>
<idno type="ISSN">0950-3579</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1995">1995</date>
<biblScope unit="volume">9</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="711">711</biblScope>
<biblScope unit="page" to="729">729</biblScope>
</imprint>
<idno type="ISSN">0950-3579</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0950-3579</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Active metabolite</term>
<term>Adverse events</term>
<term>Alevopordon</term>
<term>Alkylating agent</term>
<term>Antituberculosis drugs</term>
<term>Arthritis</term>
<term>Baciewicz</term>
<term>Bone resorption</term>
<term>British journal</term>
<term>Clinical pharmacokinetics</term>
<term>Clinical rheumatology</term>
<term>Creatinine</term>
<term>Cyclosporin</term>
<term>Cyclosporin concentrations</term>
<term>Cyclosporin dose</term>
<term>Cyclosporin metabolism</term>
<term>Cyclosporine</term>
<term>Decrease cyclosporin concentrations</term>
<term>Dos</term>
<term>Dosing</term>
<term>Dougados</term>
<term>Fauld</term>
<term>Furst</term>
<term>Grapefruit juice</term>
<term>Increase cyclosporin concentrations</term>
<term>International kidney biopsy registry</term>
<term>Kinetics</term>
<term>Landewe</term>
<term>Leflunomide</term>
<term>Leflunomide investigator brochure</term>
<term>Ludwin</term>
<term>Malignancy</term>
<term>Mcguire</term>
<term>Metabolism</term>
<term>Nitrogen mustard</term>
<term>Normal volunteers</term>
<term>Other antirheumatic drugs</term>
<term>Pharmacokinetics</term>
<term>Placebo</term>
<term>Placebo group</term>
<term>Ptachcinski</term>
<term>Renal</term>
<term>Renal biopsies</term>
<term>Renal function</term>
<term>Renal transplant patients</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatology</term>
<term>Rijthoven awam</term>
<term>Serum creatinine</term>
<term>Severe liver disease</term>
<term>Specific mechanism</term>
<term>Summary cyclosporin</term>
<term>Toxicity</term>
<term>Transplant</term>
<term>Transplant patients</term>
<term>Tugwell</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">SummaryCyclosporin A (CSA)Cyclosporin inhibits IL-2 release and T-cell activation and, secondarily, affects B-cell function. It also inhibits bone resorption, at least in vitro.This drug's bio-availability averages 25–35% but is highly variable. Food and grapefruit juice enhance bio-availability and newer formulations may make its absorption more reliable. It is highly concentrated in fatty tissues and red blood cells but does not cross the blood-brain barrier. CSA is metabolized to numerous metabolites by the liver and its elimination half-life is 6–12 hours in the absence of severe liver disease. Biliary excretion accounts for 94% of CSAs elimination. Because it is highly metabolized, its metabolism can be inhibited by other drugs (e.g. ketoconazole and erythromycin) or its metabolism can be induced (e.g. anticonvulsants).Cyclosporin is more effective than placebo for the treatment of rheumatoid arthritis and as effective as other antirhematics. There is potential for the use of CSAs in DMARD combinations.The principal toxicities of cyclosporin are gastro-intestinal and renal, with the latter being of more concern.Leflunomide (LF)Leflunomide may be a pyrinidine synthesis inhibitor, although tyrosine kinase inhibition may also be part of its mechanism of action.its active metabolite is excreted renally to a large degree, with a prolonged elimination half-life of about 11 days. Since LF is activated by liver metabolism, renal failure may have less effect on kinetics than severe liver disease.Early data on efficacy indicate efficacy at 10–25 mg/day, although more well-controlled data is necessary.Toxicity relates to the skin, liver and GI tract, although some degree of weight loss was also found.Nitrogen mustard (NM)Nitrogen mustard is an alkylating agent whose pharmacokinetics are poorly understood. Small, open studies in RA indicate that NM has a potential for relatively rapid response (1–2 weeks) but, clearly, much work remains to be done.As an alkylating agent, GI and hematological toxicities are of greatest concern.</div>
</front>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Furst, Daniel E" sort="Furst, Daniel E" uniqKey="Furst D" first="Daniel E." last="Furst">Daniel E. Furst</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B73 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B73 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:907ACA7F313227DDD461E60579F9FC6554E02941
   |texte=   Cyclosporin, leflunomide and nitrogen mustard
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021